Allergan CEO: Treasury appears to have targeted our merger

Pfizer and Allergan called off their $160 billion merger after Treasury issued new rules aimed at blocking inversions. Allergan CEO Brent Saunders discusses the new tax rules, and what investors can expect from growth at Allergan going forward.